Translational success of fundamental virology: a VSV-vectored Ebola vaccine

被引：3
|
作者：
Anderson, Elizabeth M. [1 ]
Coller, Beth-Ann G. [1 ]
机构：
[1] Merck & Co Inc, Rahway, NJ 07065 USA
来源：
JOURNAL OF VIROLOGY | 2024年 / 98卷 / 03期
基金：
美国国家卫生研究院; 英国惠康基金;
关键词：
Ebola; vaccine development; partnership; innovation; VSV-vector; rVSV Delta G-ZEBOV-GP; ZEBOV-GP VACCINE; VESICULAR STOMATITIS VIRUSES; PROTECTS NONHUMAN-PRIMATES; RESEARCH-AND-DEVELOPMENT; SIERRA-LEONE TRIAL; IMMUNIZATION PRACTICES; MEDIATED PROTECTION; ADVISORY-COMMITTEE; CLINICAL-RESEARCH; MARBURG VIRUS;
D O I：
10.1128/jvi.01627-23
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Ebola virus disease (EVD) caused by Ebola virus (EBOV) is a severe, often fatal, hemorrhagic disease. A critical component of the public health response to curb EVD epidemics is the use of a replication-competent, recombinant vesicular stomatitis virus (rVSV)-vectored Ebola vaccine, rVSV Delta G-ZEBOV-GP (ERVEBO). In this Gem, we will discuss the past and ongoing development of rVSV Delta G-ZEBOV-GP, highlighting the importance of basic science and the strength of public-private partnerships to translate fundamental virology into a licensed VSV-vectored Ebola vaccine.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV
    Fischer, T.
    Spohn, M.
    Olearo, F.
    Zinser, M. E.
    Kasonta, Rahel
    Stubbe, H. C.
    Rechtien, A.
    Ly, M. L.
    Schmiedel, S.
    Lohse, A. W.
    Grundhoff, A.
    Addo, M. M.
    Dahlke, C.
    VACCINE, 2018, 36 (46) : 7083 - 7094
  • [22] Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
    Dolzhikova, I. V.
    Zubkova, O. V.
    Tukhvatulin, A. I.
    Dzharullaeva, A. S.
    Tukhvatulina, N. M.
    Shcheblyakov, D. V.
    Shmarov, M. M.
    Tokarskaya, E. A.
    Simakova, Y. V.
    Egorova, D. A.
    Scherbinin, D. N.
    Tutykhina, I. L.
    Lysenko, A. A.
    Kostarnoy, A. V.
    Gancheva, P. G.
    Ozharovskaya, T. A.
    Belugin, B. V.
    Kolobukhina, L. V.
    Pantyukhov, V. B.
    Syromyatnikova, S. I.
    Shatokhina, I. V.
    Sizikova, T. V.
    Rumyantseva, I. G.
    Andrus, A. F.
    Boyarskaya, N. V.
    Voytyuk, A. N.
    Babira, V. F.
    Volchikhina, S. V.
    Kutaev, D. A.
    Bel'skih, A. N.
    Zhdanov, K. V.
    Zakharenko, S. M.
    Borisevich, S. V.
    Logunov, D. Y.
    Naroditsky, B. S.
    Gintsburg, A. L.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (03) : 613 - 620
  • [23] A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19
    Malherbe, Delphine C.
    Kurup, Drishya
    Wirblich, Christoph
    Ronk, Adam J.
    Mire, Chad
    Kuzmina, Natalia
    Shaik, Noor
    Periasamy, Sivakumar
    Hyde, Matthew A.
    Williams, Julie M.
    Shi, Pei-Yong
    Schnell, Matthias J.
    Bukreyev, Alexander
    NPJ VACCINES, 2021, 6 (01)
  • [24] A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19
    Delphine C. Malherbe
    Drishya Kurup
    Christoph Wirblich
    Adam J. Ronk
    Chad Mire
    Natalia Kuzmina
    Noor Shaik
    Sivakumar Periasamy
    Matthew A. Hyde
    Julie M. Williams
    Pei-Yong Shi
    Matthias J. Schnell
    Alexander Bukreyev
    npj Vaccines, 6
  • [25] Emergency Postexposure Vaccination With Vesicular Stomatitis Virus-Vectored Ebola Vaccine After Needlestick
    Lai, Lilin
    Davey, Richard
    Beck, Allison
    Xu, Yongxian
    Suffredini, Anthony F.
    Palmore, Tara
    Kabbani, Sarah
    Rogers, Susan
    Kobinger, Gary
    Alimonti, Judie
    Link, Charles J., Jr.
    Rubinson, Lewis
    Stroeher, Ute
    Wolcott, Mark
    Dorman, William
    Uyeki, Timothy M.
    Feldmann, Heinz
    Lane, H. Clifford
    Mulligan, Mark J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (12): : 1249 - 1255
  • [26] Success for three Ebola vaccine candidates in Phase 2 trials
    不详
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (04) : 847 - 847
  • [27] Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge
    Yankowski, Catherine
    Kurup, Drishya
    Wirblich, Christoph
    Schnell, Matthias J.
    NPJ VACCINES, 2023, 8 (01)
  • [28] Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge
    Catherine Yankowski
    Drishya Kurup
    Christoph Wirblich
    Matthias J. Schnell
    npj Vaccines, 8
  • [29] The VSVΔG/ZEBOV GP vaccine protects against an Ebola infection and induces humoral and cellular immunity
    Alimonti, Judie B.
    Qiu, Xiangguo
    Fernando, Lisa
    Melito, Leno
    Feldmann, Friedericke
    Stroher, Ute
    Feldmann, Heinz
    Jones, Steven
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [30] Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates
    Wong, Gary
    Richardson, Jason S.
    Pillet, Stephane
    Racine, Trina
    Patel, Ami
    Soule, Geoff
    Ennis, Jane
    Turner, Jeffrey
    Qiu, Xiangguo
    Kobinger, Gary P.
    JOURNAL OF INFECTIOUS DISEASES, 2015, 212 : S379 - S383
12345